



Best change from baseline (%)
20.0
0.0
-20.0
-30% Tumor shrinkage
-40.0
-60.0
-80.0
-100.0
Exon 19 deletion
L858R in Exon 21
Unproven partial response is stable disease
The progression of non-target lesions or the occurrence of new lesions

1a



Change from baseline (%)
100.00
80.00
60.00
40.00
20.00
0.00
-20.00
-40.00
-60.00
-80.00
-100.00
Exon 19 deletion
L858R in Exon 21
+20% Tumor growth
-30% Tumor shrinkage
Time (weeks)

1b


Fig. 1


Progression-free survival
Subject event Censored Median PFS
40 36 4 7.0 months
Censored
Progression-free survival (probability)
1.00
0.75
0.50
0.25
0 5 10 15 20 25
Time (months)
Number of people at risk 40 24 10 5 3 0


2a


Overall survival
Subject event Censored Median OS
40 13 27 NE
Censored
Overall survival (probability)
1.00
0.75
0.50
0.25
0 6 12 18 24 30
Time (months)
Number of people at risk 40 37 33 15 1 0

2b



Progression-free survival
Subject event Censored Median PFS
Exon 19 deletion 23 21 2 5.8 months
L585R 17 15 2 7.1 months
Progression-free survival (probability)
1.00
0.75
0.50
0.25
0
6
12
18
24
30
Time (months)
Exon 19 deletion
L585R
Censored
Number of people at risk
Exon 19 deletion 23 20 16 5 1 0
L585R 17 17 17 10 1 0

2c



Overall survival
Subject event Censored Median OS
Exon 19 deletion 23 9 14 NE
L585R 17 4 13 NE
Overall survival (probability)
1.00
0.75
0.50
0.25
0
6
12
18
24
30
Time (months)
Exon 19 deletion
L585R
Censored
Number of people at risk
Exon 19 deletion 23 20 16 5 1 0
L585R 17 17 17 10 1 0

2d


Fig. 2


PD-L1 expression
n=40
TMB (Mutations/Mb)
n=33
p=0.28
p=0.08
p=0.088
Objective response rate (%)
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
51.9
36.8
75.0
39.3
57.1
50.0
PD-L1 ≥1% <1% ≥10% <10% TMB ≥4.6 <4.6 (Mutations/Mb)
Number of subjects (%) 21 (52.5) 19 (47.5) 12 (30.0) 28 (70.0) 7 (21.2) 26 (78.8)


3a


Progression-free survival
Subject event Censored Median PFS
PD-L1+ 21 19 2 8.3 months
PD-L1- 19 17 2 5.8 months
Progression-free survival (probability)
1.00
0.75
0.50
0.25
PD-L1+
PD-L1-
Censored
HR=0.58 (95% CI 0.33-1.01)
p=0.05
0 5 10 15 20 25
Time (months)
Number of people at risk
PD-L1+ 21 13 7 3 2 0
PD-L1- 19 11 4 2 1 0


3b


Overall survival
Subject event Censored Median OS
PD-L1+ 21 5 16 NE
PD-L1- 19 8 11 23.5 months
PD-L1+
PD-L1-
Censored
HR=0.53 (95% CI 0.18-1.61)
p=0.26
Overall survival (probability)
1.00
0.75
0.50
0.25
0
6
12
18
24
30
Time (months)
Number of people at risk
PD-L1+ 21 19 18 9 2 0
PD-L1- 19 18 15 6 0 0

3c


Progression-free survival
Subject event Censored Median PFS
TMB high 7 6 1 8.3 months
TMB low 26 24 2 5.6 months
TMB high
TMB low
Censored
HR=0.58 (95% CI 0.25-1.34)
p=0.14
Progression-free survival (probability)
1.00
0.75
0.50
0.25
0
5
10
15
20
25
Time (months)
Number of people at risk
TMB high 7 6 1 1 1 0
TMB low 26 14 7 3 2 0

3d


Overall survival
Subject event Censored Median OS
TMB high 7 2 5 23.5 months
TMB low 26 9 17 NE
TMB high
TMB low
Censored
Overall survival (probability)
1.00
0.75
0.50
0.25
0
5
10
15
20
25
Time (months)
Number of people at risk
TMB high 7 7 7 5 2 0
TMB low 26 25 21 18 6 0

3e

Fig. 3



TMB
Effect
Change
substitution/insertion
Gene amplification
Gene deletion
Rearrangement/fusion
Truncation
Effect

Fig. 4